A gap of nearly four years separates the median age at loss of ambulation in givinostat’s open-label extension cohort from the lower bound of published natural history benchmarks for corticosteroid-treated DMD patients, and that single figure is doing a lot of work at this week’s ICNMD congress in Florence. Italfarmaco presented interim data from 225 patients in the ongoing extension study showing a median age at persistent loss of ambulation of 17.3 years (95% CI: 15.5–18.1), against a previously published natural history range of 11.0–13.4 years for corticosteroid-treated patients. That comparison is observational and cross-study, which limits causal inference, but the magnitude is hard to dismiss.
The more structurally important data come from quantitative MRI analyses of the Phase 3 EPIDYS trial, where exploratory endpoints tracked muscle composition changes across lower limb muscle groups. Contractile cross-sectional area, a direct measure of functional muscle tissue mass, differed by 0.43 to 1.20 cm² between the givinostat and placebo arms. Fat fraction differences ran from -3.4% to -4.6%. These are not the trial’s primary endpoints, so they carry the usual caveats around multiplicity and pre-specification, but they give the field a quantitative, imaging-based window into how the drug is modifying disease biology rather than just slowing a functional score. For a disease driven by progressive replacement of contractile tissue with fat and fibrosis, imaging biomarkers that track that substitution directly are exactly what clinicians need to evaluate treatment effects over time.
Givinostat received FDA approval in March 2024 for DMD patients aged six and older, and it has since been approved in the EU, UK, and UAE. Health Canada accepted a new drug submission with priority review earlier this year. The drug works as an oral HDAC inhibitor, modulating the excessive histone deacetylase activity characteristic of dystrophic muscle, and its mechanism operates independently of the underlying dystrophin mutation. That mutation-agnostic profile matters commercially and clinically in a field where several approved therapies are restricted to specific exon-skipping-amenable populations.
The OLE safety readout covering patients treated for more than ten years in a clinical setting showed no new signals beyond the established profile. That durability of the safety picture is what will matter most to prescribers weighing long-term use in pediatric patients. The metric worth tracking from here is whether Health Canada’s 180-day priority review converts to approval, because Canadian approval would be the next formal regulatory test of whether EPIDYS data translates across regulatory frameworks outside the US and EU.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
